182 related articles for article (PubMed ID: 16459719)
1. Biological markers of interferon-beta therapy: comparison among interferon-stimulated genes MxA, TRAIL and XAF-1.
Gilli F; Marnetto F; Caldano M; Sala A; Malucchi S; Capobianco M; Bertolotto A
Mult Scler; 2006 Feb; 12(1):47-57. PubMed ID: 16459719
[TBL] [Abstract][Full Text] [Related]
2. Early detection of neutralizing antibodies to interferon-beta in multiple sclerosis patients: binding antibodies predict neutralizing antibody development.
Hegen H; Millonig A; Bertolotto A; Comabella M; Giovanonni G; Guger M; Hoelzl M; Khalil M; Killestein J; Lindberg R; Malucchi S; Mehling M; Montalban X; Polman CH; Rudzki D; Schautzer F; Sellebjerg F; Sørensen PS; Deisenhammer F
Mult Scler; 2014 Apr; 20(5):577-87. PubMed ID: 24009164
[TBL] [Abstract][Full Text] [Related]
3. Neutralizing antibodies against IFN-beta in multiple sclerosis: antagonization of IFN-beta mediated suppression of MMPs.
Gilli F; Bertolotto A; Sala A; Hoffmann F; Capobianco M; Malucchi S; Glass T; Kappos L; Lindberg RL; Leppert D
Brain; 2004 Feb; 127(Pt 2):259-68. PubMed ID: 14607790
[TBL] [Abstract][Full Text] [Related]
4. Neutralizing antibodies, MxA expression and MMP-9/TIMP-1 ratio as markers of bioavailability of interferon-beta treatment in multiple sclerosis patients: a two-year follow-up study.
Garcia-Montojo M; Dominguez-Mozo MI; de las Heras V; Bartolome M; Garcia-Martinez A; Arroyo R; Alvarez-Lafuente R
Eur J Neurol; 2010 Mar; 17(3):470-8. PubMed ID: 20050906
[TBL] [Abstract][Full Text] [Related]
5. Lack of interferon-beta bioactivity is associated with the occurrence of relapses in multiple sclerosis.
van der Voort LF; Visser A; Knol DL; Oudejans CB; Polman CH; Killestein J
Eur J Neurol; 2009 Sep; 16(9):1049-52. PubMed ID: 19486142
[TBL] [Abstract][Full Text] [Related]
6. Persistent neutralizing antibodies abolish the interferon beta bioavailability in MS patients.
Bertolotto A; Gilli F; Sala A; Capobianco M; Malucchi S; Milano E; Melis F; Marnetto F; Lindberg RL; Bottero R; Di Sapio A; Giordana MT
Neurology; 2003 Feb; 60(4):634-9. PubMed ID: 12601105
[TBL] [Abstract][Full Text] [Related]
7. Analysis of neutralizing antibodies to therapeutic interferon-beta in multiple sclerosis patients: a comparison of three methods in a large Australasian cohort.
McKay F; Schibeci S; Heard R; Stewart G; Booth D
J Immunol Methods; 2006 Mar; 310(1-2):20-9. PubMed ID: 16448664
[TBL] [Abstract][Full Text] [Related]
8. Dynamics of interferon-beta modulated mRNA biomarkers in multiple sclerosis patients with anti-interferon-beta neutralizing antibodies.
Santos R; Weinstock-Guttman B; Tamaño-Blanco M; Badgett D; Zivadinov R; Justinger T; Munschauer F; Ramanathan M
J Neuroimmunol; 2006 Jul; 176(1-2):125-33. PubMed ID: 16698090
[TBL] [Abstract][Full Text] [Related]
9. Fate of multiple sclerosis patients positive for neutralising antibodies towards interferon beta shifted to alternative treatments.
Malucchi S; Capobianco M; Gilli F; Marnetto F; Caldano M; Sala A; Bertolotto A
Neurol Sci; 2005 Dec; 26 Suppl 4():S213-4. PubMed ID: 16388361
[TBL] [Abstract][Full Text] [Related]
10. Pharmacogenetics of MXA SNPs in interferon-beta treated multiple sclerosis patients.
Weinstock-Guttman B; Tamaño-Blanco M; Bhasi K; Zivadinov R; Ramanathan M
J Neuroimmunol; 2007 Jan; 182(1-2):236-9. PubMed ID: 17126411
[TBL] [Abstract][Full Text] [Related]
11. TNF-related apoptosis inducing ligand (TRAIL) as a potential response marker for interferon-beta treatment in multiple sclerosis.
Wandinger KP; Lünemann JD; Wengert O; Bellmann-Strobl J; Aktas O; Weber A; Grundström E; Ehrlich S; Wernecke KD; Volk HD; Zipp F
Lancet; 2003 Jun; 361(9374):2036-43. PubMed ID: 12814715
[TBL] [Abstract][Full Text] [Related]
12. In vivo bioactivity of interferon-beta in multiple sclerosis patients with neutralising antibodies is titre-dependent.
Sominanda A; Hillert J; Fogdell-Hahn A
J Neurol Neurosurg Psychiatry; 2008 Jan; 79(1):57-62. PubMed ID: 17911184
[TBL] [Abstract][Full Text] [Related]
13. MicroRNA-29b variants and MxA expression change during interferon beta therapy in patients with relapsing-remitting multiple sclerosis.
Fattahi M; Rezaei N; Nematalahi FS; Shaygannejad V; Fouladi S; Karimi L; Fathi F; Dehghani L; Mirmosayyeb O; Eskandari N
Mult Scler Relat Disord; 2019 Oct; 35():241-245. PubMed ID: 31421628
[TBL] [Abstract][Full Text] [Related]
14. Predictive markers for response to interferon therapy in patients with multiple sclerosis.
Malucchi S; Gilli F; Caldano M; Marnetto F; Valentino P; Granieri L; Sala A; Capobianco M; Bertolotto A
Neurology; 2008 Mar; 70(13 Pt 2):1119-27. PubMed ID: 18272865
[TBL] [Abstract][Full Text] [Related]
15. Absence of MxA induction by interferon beta in patients with MS reflects complete loss of bioactivity.
Hesse D; Sellebjerg F; Sorensen PS
Neurology; 2009 Aug; 73(5):372-7. PubMed ID: 19652141
[TBL] [Abstract][Full Text] [Related]
16. Spontaneous MxA mRNA level predicts relapses in patients with recently diagnosed MS.
van der Voort LF; Vennegoor A; Visser A; Knol DL; Uitdehaag BM; Barkhof F; Oudejans CB; Polman CH; Killestein J
Neurology; 2010 Oct; 75(14):1228-33. PubMed ID: 20921509
[TBL] [Abstract][Full Text] [Related]
17. One-year evaluation of factors affecting the biological activity of interferon beta in multiple sclerosis patients.
Malucchi S; Gilli F; Caldano M; Sala A; Capobianco M; di Sapio A; Granieri L; Bertolotto A
J Neurol; 2011 May; 258(5):895-903. PubMed ID: 21153733
[TBL] [Abstract][Full Text] [Related]
18. MxA gene expression analysis as an interferon-beta bioactivity measurement in patients with multiple sclerosis and the identification of antibody-mediated decreased bioactivity.
Pachner A; Narayan K; Price N; Hurd M; Dail D
Mol Diagn; 2003; 7(1):17-25. PubMed ID: 14529316
[TBL] [Abstract][Full Text] [Related]
19. Novel growth and death related interferon-stimulated genes (ISGs) in melanoma: greater potency of IFN-beta compared with IFN-alpha2.
Leaman DW; Chawla-Sarkar M; Jacobs B; Vyas K; Sun Y; Ozdemir A; Yi T; Williams BR; Borden EC
J Interferon Cytokine Res; 2003 Dec; 23(12):745-56. PubMed ID: 14769151
[TBL] [Abstract][Full Text] [Related]
20. Comparison of three PCR assays for the evaluation of interferon-beta biological activity in patients with multiple sclerosis.
Gilli F; Marnetto F; Stefanuto G; Rinaldi V; Farinazzo F; Malucchi S; Capobianco M; Caldano M; Sala A; Bertolotto A
Mol Diagn; 2004; 8(3):185-94. PubMed ID: 15771557
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]